Barbara Lama
University of Bologna
8 Papers
21 Citations
Barbara Lama is an academic researcher from University of Bologna. The author has contributed to research in topics: Population & Leukemia. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients
Cristina Papayannidis,Viviana Guadagnuolo,Ilaria Iacobucci,Sandra Durante,Carolina Terragna,Emanuela Ottaviani,Maria Chiara Abbenante,Federica Cattina,Simona Soverini,Barbara Lama,Lucia Toni,Wendy J. Levin,Rachel Courtney,Carmen Baldazzi,Antonio Curti,Michele Baccarani,Catriona Jamieson,Jorge E. Cortes,Vivian G. Oehler,Karen McLachlan,Todd Van Arsdale,Giovanni Martinelli +21 more
TL;DR: It is observed that 1197 genes were differentially expressed between CD34+ cells collected before and after 28 days of PF-04449913 dose finding oral therapy, and a down regulation of Bcl2 (fold change −1.03004; p value= 0.01); ABCB1 and ABCG2 are respectively up and down regulated, with a not statistically significant p-value.
8
Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients
Viviana Guadagnuolo,Cristina Papayannidis,Ilaria Iacobucci,Sandra Durante,Carolina Terragna,Emanuela Ottaviani,Maria Chiara Abbenante,Federica Cattina,Simona Soverini,Barbara Lama,Lucia Toni,Wendy J. Levin,Rachel Courtney,Carmen Baldazzi,Antonio Curti,Michele Baccarani,Catriona Jamieson,Jorge E. Cortes,Vivian G. Oehler,Karen McLachlan,Todd Van Arsdale,Giovanni Martinelli +21 more
TL;DR: This data demonstrates thatPF-04449913 specifically targets the Hh Pathway in CD34+ cells, suggesting that Hh inhibition may impair leukemia stem cell maintenance and identify several new potential biomarkers for the PF-044 49913.
5
RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.
Stefania Paolini,Emanuela Ottaviani,Sarah Parisi,Federica Salmi,Barbara Lama,Antonio Curti,Daniela Cilloni,Anna Candoni,Ernesto Vigna,Cristina Clissa,Carlo Finelli,Ilaria Iacobucci,Claudio Laterza,Cristina Papayannidis,Pier Paolo Piccaluga,Nicola Vianelli,Giuseppe Saglio,Renato Fanin,Fortunato Morabito,Alfonso Zaccaria,Francesco Lauria,Marco De Gobbi,Dino Amadori,Michele Baccarani,Giovanni Martinelli +24 more
TL;DR: The clinical efficacy of the combination Tipifarnib-Bortezomib was similar to what reported for Tip ifarnib alone, and it was confirmed that the RASGPR1/APTX BM or PB level is an effective predictor of response.
3
Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients
Viviana Guadagnuolo,Cristina Papayannidis,Ilaria Iacobucci,Sandra Durante,Carolina Terragna,Emanuela Ottaviani,Maria Chiara Abbenante,Federica Cattina,Simona Soverini,Barbara Lama,Lucia Toni,Wendy J. Levin,Rachel Courtney,Carmen Baldazzi,Antonio Curti,Michele Baccarani,Catriona Jamieson,Jorge E. Cortes,Vivian G. Oehler,Karen McLachlan,Todd VanArsdale,Giovanni Martinelli +21 more
TL;DR: This data demonstrates that PF-04449913 specifically targets the Hh Pathway in CD34+ cells, suggesting that Hh inhibition may impair leukemia stem cell maintenance and may be useful for pts selection strategies and subsequent eradication of the LSC.
2
Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia
Stefania Paolini,Emanuela Ottaviani,Barbara Lama,Federica Salmi,Cristina Clissa,Antonio Curti,Carlo Finelli,Panagiota Giannoulia,Ilaria Iacobucci,Claudio Laterza,Cristina Papayannidis,Sarah Parisi,Pier Paolo Piccaluga,Nicola Vianelli,Giuseppe Saglio,Renato Fanin,Fortunato Morabito,Alfonso Zaccaria,Francesco Lauria,Dino Amadori,Michele Baccarani,Giovanni Martinelli +21 more
TL;DR: A phase I/II study aiming to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of V in association with standard doses of Z and the efficacy and toxicity of the combination found the association seemed to be safe, with response rate similar to what reported for Z alone.
2